Board of Directors
Peter has a wealth of experience and has held key senior positions, including Chairman, CEO and CFO in a number of companies in the healthcare industry, and played a significant role in their growth.
Peter spent 12 years at Celltech Group plc (1992–2004) as CFO and Deputy CEO, six years at ProStaken Group plc as Chairman (2007–2013) and interim CEO (2010–2011) and three years as Chairman of Proximagen Neurosciences plc (2009-2012).
Peter is currently Chairman of None Advanced Medical Solutions Plc, Future Plc and Diurnal Plc and Non-Executive Director of Oxford Nanopore Technologies Ltd and Macrotarg Ltd.
Shaun in the Chief Executive Officer of the Clinigen Group and has the responsibility for the Group achieving its key performance indicators and plays a central role in setting the Group strategy.
Shaun joined Clinigen in January 2012 as Chief Operating Officer, progressed to Deputy CEO in July 2015 and became CEO in November 2016.
Shaun has over 25 years of international experience in both the pharmaceutical industry and the life sciences services industry. Shaun has overseen the development and sustained growth of a number of businesses across the pharmaceutical lifecycle and has a track record of leading and developing high quality, effective management teams.
Prior to joining Clinigen, Shaun held senior global strategic, commercial and operational roles at Pfizer, Sanofi, Wolters Kluwer Health and the KnowledgePoint360 Group (now part of UDG Healthcare).
Martin joined Clinigen in August 2015 and has over 19 years’ experience working for international, listed companies.
Before Clinigen, Martin worked for Hays plc, Europe’s largest professional recruitment business. He began there as Head of Investor Relations and M&A before becoming Finance Director for the Continental Europe and Rest of World division, which operated across 21 countries with revenues of over £1bn. Prior to that, Martin held several financial roles at the FTSE 100 logistics group, Exel plc (now part of Deutsche Post), including Financial Controller of two of the UK divisions. He is a qualified Chartered Accountant, having trained at PwC in the M&A Transaction Services team.
John has over 30 years’ experience as a corporate lawyer, dealing with corporate finance and commercial contract issues across a number of industries. He was formerly Managing Partner at Ricksons LLP and subsequently became a Partner at DWF LLP.
John is currently a Director of Wichtig International Ltd.
Ian has considerable experience as both an Executive Director and as a Non-Executive Director. Ian is CEO of F2G Limited.
Ian currently holds positions as Non-Executive Director of Consort Medical plc and Bioventix plc, where he is the Non-Executive Chairman. Ian is also Chairman of the Investment Committee at Cancer Research UK Pioneer Fund, Director of Casewell Consulting Ltd, F2G Ltd, and Wells Stores Ltd, and an Operating Partner at Advent Life Sciences LLP.